Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2020-05-04
Buyer: Sykehusinnkjøp HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 2100000 NOK
Award criteria: Lowest price

Technical requirements: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3: the Active Ingredients List.
A new need has arisen after the contracts were signed for contracts for the delivery of Labetolol for infusion (ATC code C07AG01) as the selected supplier has announced that the delivery of their product cannot be maintained.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3: the Active Ingredients List.
A new need has arisen after the contracts were signed for contracts for the delivery of Labetolol for infusion (ATC code C07AG01) as the selected supplier has announced that the delivery of their product cannot be maintained.
Due to this, LIS intends to enter into contracts between the regional health trusts (the contracting authorities) and Macure Pharma ApS (the supplier) as an additional contract to LIS 2001c, i.e., the scope and length of the contract must follow the mentioned procurement.
(Hereunder access to extension and cancellation), without the announcement of a new competition for this active ingredient. The health companies that are under the regional health trusts have an option to join the contracts.
LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest, or that a supplier other than Macure Pharma ApS can deliver the product in the contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to make the procurement without a competition. Refer to the public procurement regulation § 21-5, cf. § 21-2, cf. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.
LIS requests that those who have objections to this submit feedback before the waiting period expires on 7 May 2020. If no objections are received, a contract will be signed after the waiting period has expired.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3: the Active Ingredients List.
A new need has arisen after the contracts were signed for contracts for the delivery of Labetolol for infusion (ATC code C07AG01) as the selected supplier has announced that the delivery of their product cannot be maintained.
Due to this, LIS intends to enter into contracts between the regional health trusts (the contracting authorities) and Macure Pharma ApS (the supplier) as an additional contract to LIS 2001c, i.e., the scope and length of the contract must follow the mentioned procurement.
(Hereunder access to extension and cancellation), without the announcement of a new competition for this active ingredient. The health companies that are under the regional health trusts have an option to join the contracts.
LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest, or that a supplier other than Macure Pharma ApS can deliver the product in the contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to make the procurement without a competition. Refer to the public procurement regulation § 21-5, cf. § 21-2, cf. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.
LIS requests that those who have objections to this submit feedback before the waiting period expires on 7 May 2020. If no objections are received, a contract will be signed after the waiting period has expired.


Winner: Macure Pharma ApS
Award value: 2100000